Financial Statement 1 January - 31 December 1999

Financial Statement 1 January - 31 December 1999 * Profit after financial items was SEK 21.3 (-38.8) m. Turnover increased to SEK 189.4 (69.5) m. and the company shows a positive cash flow. * CCS increased its sales by 14.7% to SEK 70.2, while increasing operating profit to SEK 9.4 (6.1) m. * Phase II trials with MIV-606 against shingles completed with favorable results; Medivir bought back this anti-shingles agent from Abbott at the beginning of the year. * MIV-150 against HIV outlicensed to Chiron. At the beginning of phase I trials, Medivir had received a total of USD 12.6 m in payment for this anti-HIV agent. Another two key agreements were signed with Chiron. * Collaboration with AstraZeneca relating to herpes cream ME-609 progressed favorably. Phase II trials began after positive phase I results. * The revitalized Medivir MIV-310 compound proves effective against multi-resistant HIV; phase II trials planned. ------------------------------------------------------------ Please visit http://www.bit.se for further information The following files are available for download: http://www.bit.se/bitonline/2000/02/09/20000209BIT00220/bit0001.doc http://www.bit.se/bitonline/2000/02/09/20000209BIT00220/bit0002.pdf

About Us

Medivir develops innovative pharmaceuticals for the treatment of cancer. The company specializes within protease inhibitor research and nucleotide/nucleoside science.The research is conducted in all phases of pharmaceutical development, from idea to clinical phase III studies. The development work is conducted both in-house and through partnerships.Medivir is listed on the Nasdaq Stockholm Mid Cap List.

Subscribe